Jenner Institute

Yesterday, we had the honour of receiving Prof Halidou Tinto, head of the Clinical Research Unit of Nanoro (CRUN / URCN), at the Jenner Institute for a seminar on the international partnership for health research in Africa. His inspirational talk focussed on his scientific journey from the creation of CRUN as the first clinical research facility in Burkina Faso to the crucial role played by the institute in the fight against malaria in recent years. His team led the phase I/IIb clinical trial for R21/Matrix-M and was part of the phase III clinical trials of both R21/Matrix-M and RTSS, along with other African collaborators. Prof Tinto also spoke about the need for African Research Institutions to direct their own research agenda and how important it is to maintain a critical mass of expertise within countries. Over lunch, we discussed what role early career researchers at the Jenner Institute can play in this process. Here’s to many more collaborations with talented African scientists taking the lead! #Malaria #VaccineResearch #R21 #Collaboration

Congratulations to the R21/MatrixM vaccine team on these two studies, led by Prof Sir Adrian Hill and published in The Lancet Microbe. The first paper reports two phase 1, first-in-human trials evaluating the safety of R21 administered alone or adjuvanted with Matrix-M (Novavax) in either UK or Burkinabe adults. The vaccine was shown to be safe and well-tolerated. The second reports results from a phase 1–2A trial, which evaluated the efficacy of the R21/Matrix-M vaccine using Controlled Human Malaria Infection. This work demonstrated high efficacy of R21/Matrix-M against clinical malaria in UK adults with no history of malaria. These two studies played a pivotal role in the progress of the R21/Matrix-M toward qualification and licensing. R21/Matrix vaccine, manufactured by the Serum Institute of India Pvt. Ltd. is now distributed in 17 countries and aims to contribute to decreased Malaria burden worldwide in the following years. Read the full studies in Lancet Microbe https://lnkd.in/ehyCZQiC https://lnkd.in/eB66b8hp Congratulations to all the authors! #malaria #R21 #vaccine #clinicaltrials

Recently, the Jenner Institute team working on the R21 vaccine attended the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) held in New Orleans, USA. The days were packed with exciting presentations and posters, sharing the latest advances and knowledge on a wide range of global health issues, but also addressing fundamental questions for the future. The Jenner Institute had the chance to be part of a variety of sessions;   Prof Sir Adrian Hill was part of a panel of speakers who discussed malaria prevention, and in particular the development and deployment of the R21 vaccine and pipeline vaccines from Oxford, as well as integration with other tools to combat the burden of malaria in Africa. Mehreen Datoo (with Emma Beaumont) presented an update on the progress of the phase III R21/Matrix-M trial with data on additional booster doses and vaccine efficacy measured to date. Lisa Stockdale presented immunology data from the Phase 3 R21/Matrix-M clinical trial, reporting IgG levels and decay of NANP, C-term, full-length R21 and Hepatitis B surface antigen-specific antibodies. Fernando Ramos presented safety and immunogenicity data of R21/Matrix-M in children living with HIV after the primary series of vaccinations from the ongoing trial in Uganda.   Sam Morys presented on the comparative immunogenicity of the R21/Matrix-M malaria vaccine across age groups and geographies. Olivia Muñoz presented a comparative study of antibody effector functions with participants vaccinated with either RTS,S/AS01 or R21/Matrix-M enrolled in controlled human malaria infection studies in the UK. #ASTMH #R21 #Vaccine #Malaria #Tropmed

Very proud to be involved in HIV research here at the Jenner! Successful functionally curative treatments for HIV would completely alter the landscape of care, and bring us one step closer to the eradication of AIDS. #WorldAIDSDay

On Thursday, Nigeria announced the rollout of the R21 malaria vaccine co-developed by Jenner Institute, Serum Institute of India Pvt. Ltd. and Novavax. This marks a significant milestone in the country's fight against the deadly disease. Find out more 👉 https://lnkd.in/eStJCy_9

We are very proud of Mehreen Datoo, a Jenner Institute Clinical research fellow who has been named on the TIME100 Next list for her work on progressing the R21/Matrix-M malaria vaccine. The vaccine, developed by the Jenner Institute, University of Oxford, was recommended for use by the World Health Organization and started roll-out in July this year. The TIME100 Next list spotlights 100 rising stars who are shaping the future of business, entertainment, sports, politics, science, health and more. Congratulations Mehreen! 🌟 #malaria #vaccine #R21 #TIME100 https://lnkd.in/efx6cWyQ

HAVE WE BEATEN MALARIA? 🦟🧬💉🧫🥼 More than half a million people die of #malaria every year. With 2 #vaccines recommended for use, Lisa Stockdale and Andrew Duncan from the University of Oxford will discuss what the prospects are for eliminating malaria and how long it might take. Join them on 11th September at https://lnkd.in/echp57mD #SMLATES

Yesterday, the new R21/Matrix-M™ malaria vaccine was rolled out in Côte d'Ivoire, which became the first country to vaccinate a child in Abidjan. This is a first critical step in the global fight against malaria. Between 2024 and 2025, 6.6 million children are expected to be vaccinated in 15 African countries with the support of Gavi, the Vaccine Alliance. R21/Matrix-M™ was co-developed by the Jenner Institute at the University of Oxford and Serum Institute of India Pvt. Ltd. using Novavax’s Matrix-M™ adjuvant. Serum Institute of India Pvt. Ltd. is committed to scaling up to 100 million doses annually in the future. #malaria #vaccine #R21 https://lnkd.in/gsQZjUUM

Congratulations to Prof Alexander (Sandy) Douglas and the team from the Jenner Institute and AstraZeneca for being the runners-up for the 2024 MacRobert Award from the Royal Academy of Engineering for their engineering innovation in the manufacturing of the COVID vaccine. Find out more 👉 https://lnkd.in/eRbMvFcZ

The Hill Group at the Jenner Institute, Nuffield Department of Medicine is seeking a Programme Manager, with responsibility for  providing management support to a range of pre-clinical and translational projects led by Professor Hill. The group’s translational activity is underpinned by a strong programme of preclinical work, seeking to identify new vaccine targets, and to design and validate future generations of vaccines. Previously, our principal focus has been upon the development of malaria vaccines using replication-deficient viral vector platforms. More recently, we have developed a virus-like particle approach, which is currently undergoing clinical evaluation. For more information, please visit: https://lnkd.in/etJSuwck The main responsibilities of this role will be to undertake the financial management of the Hill group portfolio of pre-clinical and translational grant funding including approving requisitions and financial reporting, as well as being responsible for the strategic management of the novel Rvx21 clinical trials in locations such as the UK, Thailand and Indonesia, including financial management, coordination of sites, regulatory approvals and overall Project coordination. For more information on this exciting opportunity, please see the link below; https://lnkd.in/ePe_cp_S #programmemanager #malariavaccine #oxforduniversity #wearehiring